Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.

OBJECTIVE To evaluate the effect of treatment with alendronate sodium, a potent aminobisphosphonate, on the incidence of nonvertebral fractures in postmenopausal women with osteoporosis. DATA SOURCES Published data and data on file at Merck Research Laboratories. STUDY SELECTION All completed prospective, randomized, placebo-controlled alendronate trials of at least 2 years' duration (5 studies). DATA EXTRACTION All subjects were women with osteoporosis between the ages of 42 and 85 years, postmenopausal at least 4 years, with lumbar spine bone mineral density (measured using dual-energy x-ray absorptiometry) at least 2.0 SD below the mean for young adult women. All women randomized to treatment with placebo or alendronate at a dose higher than 1 mg per day for at least 2 years were included. DATA SYNTHESIS In the placebo group (n=590), 60 women reported nonvertebral fractures during 1347 patient-years at risk (overall rate, 4.45 women with fractures per 100 patient-years at risk). In the alendronate group (n = 1012), 73 women reported nonvertebral fractures during 2240 patient-years-at risk (overall rate, 3.26 women with fractures per 100 patient-years at risk). The estimated cumulative incidence of nonvertebral fractures after 3 years was 12.6% in the placebo group and 9.0% in alendronate group. The relative risk for nonvertebral fracture estimated using the Cox proportional hazards model was 0.71 (95% confidence interval,0.502-0.997) (P=.048). A reduction in risk was consistent across each of the studies and at each major site of osteoporotic fracture, including the hip and wrist. CONCLUSION In postmenopausal women with osteoporosis, treatment with alendronate reduces the risk of nonvertebral fractures over at least 3 years.

[1]  P. Ridker,et al.  Discordance between Meta-analyses and Large-Scale Randomized, Controlled Trials: Examples from the Management of Acute Myocardial Infarction , 1995, Annals of Internal Medicine.

[2]  G. Spears,et al.  Treatment of postmenopausal osteoporosis with calcitriol or calcium , 1992 .

[3]  S Phillips,et al.  The direct medical costs of osteoporosis for American women aged 45 and older, 1986. , 1988, Bone.

[4]  M. A. Hansen,et al.  Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. , 1992, BMJ.

[5]  Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy , 1993 .

[6]  L. Bouter,et al.  Vitamin D Supplementation and Fracture Incidence in Elderly Persons , 1996, Annals of Internal Medicine.

[7]  P. Delmas,et al.  Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. , 1994, The Journal of clinical endocrinology and metabolism.

[8]  A. Lane,et al.  Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen , 1992, Annals of Internal Medicine.

[9]  William M. O'Fallon,et al.  Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. , 1990 .

[10]  S. Ortolani,et al.  Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. , 1995, Bone.

[11]  L. Melton,et al.  The prevention and treatment of osteoporosis. , 1992, The New England journal of medicine.

[12]  S. Cummings,et al.  Which Fractures Are Associated with Low Appendicular Bone Mass in Elderly Women , 1991 .

[13]  S. Cummings,et al.  The accuracy of self-report of fractures in elderly women: evidence from a prospective study. , 1992, American journal of epidemiology.

[14]  R B Wallace,et al.  A model of lifetime osteoporosis impact. , 1991, Archives of internal medicine.

[15]  S. Cummings,et al.  Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. , 1989, Archives of internal medicine.

[16]  G. Rodan,et al.  Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. , 1991, The Journal of clinical investigation.

[17]  François Duboeuf,et al.  Vitamin D3 and Calcium to Prevent Hip Fractures in Elderly Women , 1992 .

[18]  H. Genant,et al.  Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. , 1990, The New England journal of medicine.

[19]  S. Cummings,et al.  The future of hip fractures in the United States. Numbers, costs, and potential effects of postmenopausal estrogen. , 1990, Clinical orthopaedics and related research.

[20]  W. O'Fallon,et al.  Long‐term fracture prediction by bone mineral assessed at different skeletal sites , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  J. Kanis,et al.  Perspective : The diagnosis of osteoporosis , 1994 .

[22]  H. Genant,et al.  Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. , 1995, The American journal of medicine.

[23]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[24]  W. Mysiw,et al.  Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. , 1990, The New England journal of medicine.

[25]  J Dequeker,et al.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.

[26]  B. Adams-Huet,et al.  Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial , 1995, Annals of Internal Medicine.